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A significant challenge in chemistry is to rationally reproduce the functional potency of a
protein in a small molecule, which is cheaper to manufacture, non-immunogenic, and also
both stable and bioavailable. Synthetic peptides corresponding to small bioactive protein
surfaces do not form stable structures in water and do not exhibit the functional potencies of
proteins. Here we describe a novel approach to growing small molecules with protein-like
potencies from a functionally important amino acid of a protein. A 77-residue human
inflammatory protein (complement C3a) important in innate immunity is rationally trans-
formed to equipotent small molecules, using peptide surrogates that incorporate a turn-
inducing heterocycle with correctly positioned hydrogen-bond-accepting atoms. Small
molecule agonists (molecular weight o500Da) examined for receptor affinity and cellular
responses have the same high potencies, functional profile and specificity of action as C3a
protein, but greater plasma stability and bioavailability.
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P
rotein–protein interactions underlie most biological
processes defining life, aging, disease and death. However,
the use of proteins in science, industry and medicine is still
significantly restricted by their high cost of manufacture, chemical
instability, immunogenicity and poor bioavailability. The need to
overcome these deficiencies has driven many chemical efforts, but it
has been extremely challenging to reproduce the exquisitely potent
and specific actions of proteins1–6. The biological functions of some
proteins are localized in very short polypeptide segments stabilized
in specific structures (two to four helical turns, isolated b-turns,
strands/sheets, and their combinations) by their protein
environments7,8. Yet, even in these simpler cases, short synthetic
peptides corresponding to bioactive protein components do not
display functional potencies comparable to proteins and are not
thermodynamically stable structures in water, where they instead
adopt random interconverting structures9.
An important example of a protein to functionally mimic is the
human complement protein C3a. This is a 9 kDa helix bundle that
plays key roles in innate immune responses to infection and tissue
injury by interacting with a 100kDa cell surface protein, a G protein-
coupled receptor (GPCR) called C3aR10–12. C3a is a powerful pro-
inflammatory agent that recruits immune cells to sites of infection
(chemotaxis) and induces immune cells to secrete bactericidal agents
(via degranulation) as well as inflammatory cytokines13,14.
Overexpression of C3a/C3aR or sustained activation of its receptor
can lead to inflammatory diseases, including allergies10, asthma15,
arthritis16, sepsis17, lupus18, diabetes19, psoriasis20, nephropathy21,
ischaemia-reperfusion injury22, obesity, and metabolic and
cardiovascular dysfunction23. C3a also reportedly has
antimicrobial24 and antifungal25 activities. Despite these potent
activities, C3a is rapidly degraded in vivo to C3a-desArg26, which
has a different pharmacology from C3a and does not bind to
C3aR27, nor do commercially available antibodies discriminate
between C3a and C3a-desArg22. Synthetic agonists that act through
C3aR, but do not degrade as C3a does, can be expected to have
immunostimulating and degranulating activities, whereas stable
antagonists may be valuable new anti-inflammatory therapeutics.
However, despite decades of effort by academia and the
pharmaceutical industry, no small organic molecules have yet been
reported as potent and selective C3aR agonists or antagonists28–32.
The crystal structure of C3a33–35 reveals that its 77 amino acids
adopt a well-defined helix bundle (Fig. 1a), with less structure in
carboxy-terminal residues known to be critical for receptor
activation36. Mutagenesis of C3a and its receptor support a two-
site binding model37. The helical bundle residues 1–69 of C3a
have high affinity for (but do not activate) the receptor, through
multiple positive-charged lysine and arginine residues of C3a
making complementary interactions with negative-charged Asp
residues in the unusually large extracellular loop 2 (ECL2) at one
site of the C3aR38,39. On the other hand, the C-terminal
pentapeptide segment LGLAR of C3a has very low affinity for a
second site on C3aR, leading to activation. Arg77 at the C-
terminus of C3a is critical for agonist activity; on removal, the
resulting C3a-desArg does not bind to C3aR27. Moreover,
mutagenesis of Arg161, Arg340 and Asp417 in the receptor has
shown these residues to be crucial for C3a binding and
activation40. The essential Arg77 residue is the only charged
residue near the C terminus of C3a and is thought to interact with
the above three charged residues of C3aR.
Here we exemplify the approach of growing a functionally
important amino acid of a protein, namely the arginine from the
C-terminus of C3a, into small molecules that can execute
the potent functions of the C3a protein, but are only a fraction
of the size, cheaper to synthesize, and more chemically and
biologically stable. We describe small molecules built from an
amino acid template, incorporating a specific heterocycle to make
important hydrogen bonds (H-bonds) with the C3a receptor and
to control the shape of the molecule and orientation of its
hydrophobic substituents. The small molecules have similar
affinity for C3aR on human macrophages and comparable agonist
potencies and functional profiles to C3a, as measured by
intracellular calcium release and inflammatory gene expression
in human macrophages and degranulation of human mast cells.
Importantly, the small molecule agonists are stable in serum,
unlike C3a that rapidly degrades with loss of the C-terminal
arginine that is critical for binding of C3a to its receptor C3aR. If
generally applicable, this template approach could potentially be
useful in creating small molecule surrogates of other proteins for
applications in biology and medicine.
Results
C3aR homology model and ligand evolution. We therefore
created a three-dimensional homology structural model for C3aR
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Figure 1 | Modelling C3aR interactions with Leu–Ala–Arg. (a) Structure of
human C3a (pdb 4I6O). (b) Side view of seven transmembrane (7TM)
region of C3aR homology model derived from the crystal structure of
human CXCR4 (bound to a cyclic peptide antagonist)41. Ca of D417, R161,
R340, H418 and Y393 rendered as solid spheres. (c) Ac–Leu–Ala–Arg
(3, yellow) placed in the 7TM region of human C3aR, showing putative
interactions with receptor residues D417 (TM7), R161 (TM4) and R340
(TM5) identified from mutagenesis38–40 to be important for binding to
Arg77 of C3a. (d) A low-energy conformation of Ac–(Leu–Ox)–Arg (6, cyan
carbons; Ox, oxazole) aligned well with Ac–Leu–Ala–Arg (3, green carbons)
modelled in a type IIb turn conformation (fiþ 1  60, ciþ 1 120, fiþ 2 80,
ciþ 2 0), showing the typical (i,iþ 3) H-bond Ac–COyHN–Arg
(Arg side chains omitted for clarity).
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(Fig. 1b) and positioned only an arginine amino acid into C3aR in
the vicinity of those three receptor residues (Fig. 1c). A homology
model of the human C3a receptor was generated, using the Prime
module in the Schro¨dinger molecular modelling suite, based
on aligning its sequence with that of the crystal structure of
human chemokine receptor CXCR4 (bound to a cyclic peptide
antagonist)41 (pdb code 3OE0). Models were created to focus
on the seven transmembrane (7TM) helix domain, without the
ECL2, which in C3aR consists of 170 amino acids and is
inherently flexible and difficult to model (Fig. 1b). An arginine
molecule was specifically placed in this model, near receptor
residues Arg161, Arg340 and Asp417, to simulate Arg77 of the
C3a ligand. The negatively charged carboxylate terminus of
Arg77 in C3a interacts with cationic side chains of both Arg161
and Arg340, whereas the protonated guanidinium side chain of
Arg77 interacts with the carboxylate side chain of Asp417
(Fig. 1c). These three contact points are consistent with C3aR/
C3a mutagenesis data, indicating complementarity between
Arg77 in C3a and the above three residues of C3aR38–40. On
the basis of this location for Arg77, we identified space that could
be occupied by attached amino acids Ala76 and Leu75 of C3a,
thereby indicating where a small tripeptide ligand LAR might
bind in C3aR. This was the basis for our strategy to rationally
design and grow novel small molecule ligands from an arginine
point template corresponding to Arg77 of C3a, notwithstanding
the large uncertainties of ligand docking in a three-dimensional
model of a GPCR.
Structure–activity relationships. Tripeptides Leu–Ala–Arg (2),
Ac–Leu–Ala–Arg (3) and Boc–Leu–Ala–Arg (4) did not show
any detectable binding to C3aR or agonist activity at or below
1mM, the highest concentration tested, on human monocyte-
derived macrophages (HMDMs) (Table 1). Next, we sought to
establish whether there were residues present in the 7TM-binding
cavity and/or the ECLs that could potentially form additional
H-bonding interactions with the backbone of Leu or Ala from the
tripeptide Leu–Ala–Arg. Three receptor residues were con-
spicuous as prospective H-bond donors in the proximity of the
Ala attached to Arg, namely Tyr393 from TM6 and His418 from
TM7 (Fig. 1c), and possibly Tyr174 from ECL2, although the
latter position is very uncertain owing to ECL2 flexibility.
Table 1 | Binding affinity and agonist potency of ligands for C3aR on human macrophages.
Compound Binding IC50 (nM)* Binding pIC50±s.e.m. n Agonist EC50 (lM)w Agonist pEC50±s.e.m. n
1 C3a 0.07 10.1±0.2 43 0.04 7.4±0.07 3
2 Leu–Ala–Arg 41,000,000 o4.0 3 41,000 o4.0 3
3 Ac–Leu–Ala–Arg 41,000,000 o4.0 3 41,000 o4.0 3
4 Boc–Leu–Ala–Arg 41,000,000 o4.0 3 41,000 o4.0 3
5 H–(Leu–Oxazole)–Arg 560 6.2±0.4 3 4100 o4.0 3
6 Ac–(Leu–Oxazole)–Arg 30 7.5±0.2 3 0.17 6.8±0.1 3
7 Boc–(Leu–Oxazole)–Arg 12 7.9±0.2 8 0.06 7.2±0.1 3
8 Boc–(Ile–Oxazole)–Arg 34 7.5±0.2 3 0.02 7.7±0.2 3
9 Boc–(Cha–Oxazole)–Arg 99 7.0±0.2 3 0.21 6.7±0.3 3
10 Boc–(Ala–Oxazole)–Arg 4100,000 o4.0 3 4100 o4.0 3
11 Boc–(Leu–Thiazole)–Arg 375 6.4±0.3 3 z z 3
12 Boc–(Leu–Imidazole)–Arg 51 7.3±0.3 3 0.12 6.9±0.1 3
13 Boc–(Leu–N–Me(Y)–Imidazole)–Arg 47 7.3±0.3 3 0.06 7.2±0.1 3
14 Boc–(Leu–N–Me(X)–Imidazole)–Arg 410,000 o5.0 3 9.4 5.0±0.1 3
15 Boc–(Leu–1,3,4-Oxadiazole)–Arg 997 6.0±0.5 3 4100 o4.0 3
16 3-Indole–(Leu–Imidazole)–Arg 12 7.9±0.3 3 0.015 7.8±0.3 4
17 3-Indole–(Leu–Oxazole)–Arg 4 8.4±0.3 5 0.007 8.1±0.2 4
EC50, half maximal effective concentration; HMDM, human monocyte-derived macrophage; IC50, half maximal inhibitory concentration.
*Concentration of ligand required to inhibit 50% of [125I]-C3a (80 pM) binding to HMDMs.
wConcentration of ligand causing 50% of Ca2þ release in HMDMs relative to 100% induced by C3a at 1 mM.
zThis compound showed partial agonist activity at concentrations Z1 mM.
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Figure 2 | Synthesised C3aR ligands. Chemical structures of compounds 5–17, synthesized as detailed in the Methods (16,17) and Supplementary
Methods (5–15).
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Although GPCR models are notoriously flexible and thus of
uncertain accuracy, we decided to test whether H-bond acceptors
strategically placed at the Ala position might increase affinity for
C3aR, thereby confirming the idea that an H-bond donor might
be nearby its binding site in C3aR. Ala in Leu–Ala–Arg was
therefore replaced with oxazole (Ox), which positions a known
H-bond-accepting nitrogen atom of Ox within (Leu–Ox)–Arg for
potential interaction with a putative H-bond donor Tyr393,
His418 or Tyr174. This ligand change from Leu–Ala–Arg (2) to
(Leu–Ox)–Arg (5) resulted in a 41,000-fold increase in affinity
for C3aR and some measurable, albeit weak, agonist activity
(Table 1). Importantly, structure–activity optimization does not
rely on knowing the identity of the interacting H-bond donor in
C3aR. Figure 2 details the chemical structure of ligand 5 and
further modified ligands 6–17 to be discussed below.
The magnitude of the increase in affinity cannot be accounted
for solely by one H-bond to the Ox, and is in part also attributed
to the known turn-inducing constraint imposed by this hetero-
cycle, conferring some structure in water to an otherwise
unstructured tripeptide unit. Most peptide-activated GPCRs bind
to a b/g-turn conformation of endogenous agonists42, and
incorporation of a turn mimetic often pre-organizes agonists in
a receptor-bound turn conformation. An alignment using ROCS
(rapid overlay of chemical structures, version 3.1.2, OpenEye
Scientific Software) of low-energy conformers generated with
Omega (version 2.4.3, OpenEye Scientific Software) of Ac–Leu–
Ala–Arg (3) with Ac–(Leu–Ox)–Arg (6) indicated that a b-turn
conformation of the former was mimicked by the latter (Fig. 1d).
The plane of the Ox ring is perpendicular to the plane of the Leu
amide carbonyl, favourably aligning for making a H-bond
interaction (Fig. 1d). In support of formation of this additional
H-bond, attaching a carbonyl group to the amino terminus of 5
(for example, Ac in Ac–(Leu–Ox)–Arg, 6; Boc in Boc–(Leu–Ox)–
Arg, 7) causedB20- andB50-fold increases in ligand affinity for
C3aR andB103-fold greater agonist activity than for 5 (Table 1).
In combination, these data support both the heterocycle nitrogen
and the N-terminal carbonyl oxygen being important H-bond
acceptors that contribute to the spectacular increase in receptor
binding and agonist function.
Modifying side chains and heterocycles. Further modifications
of the leucine side chain to isoleucine (8) caused a 3-fold loss of
affinity, to the larger side chain of cyclohexylalanine (9) reduced
binding affinity 8-fold and agonist potency 3-fold, whereas
reducing the size of the side chain to alanine (10) reduced affinity
and agonist activity by over 1,000-fold. Thus, the leucine side
chain is important and essential for binding to C3aR and con-
tributes a factor of at least 103 to agonist binding and function.
On the basis of the promising results for Ox in compound 7,
other five-membered aromatic heterocycles were incorporated to
identify the contribution of the heterocycle H-bond acceptor to
agonist potency. The theoretical H-bond interaction energy
between a water molecule and each heterocycle was determined
using models minimized by ab initio methods at the MP2/6
311þþ g(3d,3p) level of theory using Gaussian 09 (ref. 43).
Strong interactions were predicted for the trigonal nitrogen atoms
of imidazole and Ox rings, whereas much weaker H-bonds are
likely for the oxygen of oxadiazole and sulphur or p system of
thiazole. N-methylation in the inactive compound 14 precluded
H-bond formation, so the H-bond interaction energy was set at
zero (Fig. 3a). For this small series of heterocycles incorporated
into Boc–Leu–Ala–Arg to produce compounds 7 and 11–15,
there was a linear correlation between H-bond interaction energy
(over a 35 kJmol 1 range), calculated for the respective H-bond
acceptor interacting with water, and the binding affinity (over 4
log units) of the ligand for C3aR (Fig. 3b,c). Positioning of the
H-bond-accepting atom was an important determinant of agonist
potency, the X position being more important than Y or Z
positions (Table 1), highlighted by the N-methyl imidazole
substituents in 13 versus 14.
Having identified imidazole and Ox as optimal heterocycle
modifications, the N-terminal Boc group was next replaced to
seek greater agonist potency. The indole-3-carboxamide deriva-
tives 16 and 17 showed approximately threefold greater binding
affinity and almost tenfold greater agonist activity than 12 and 7,
respectively. These observed enhancements may be due to the
indole ring making an additional p-stacking interaction with
His418 and occupying a larger region of hydrophobic space in the
C3a receptor. Concentration–response curves are compared
(Fig. 4a) for C3a versus the most potent small molecule agonist
above, compound 17 (also named TR16), in the intracellular
Ca2þ release assay using HMDMs. It is apparent that 17 shows a
full agonist response comparable to C3a, but that 17 is almost an
order of magnitude more active (EC50 (half maximal effective
Me
N
N N N
N N
N
NN
S
H Me
O O
H
H H
H
O
H H
O
O
O
OO
H H H
H
HN
H
–35.3 –34.0
100
80
60
40
20
0
–12
10
12 7
11
15
14
R2 = 0.9
13
8
6
4
2
0
–40
Calculated H-bond energy (kJ mol–1)
–30 –20 –10 0
Bi
nd
in
g 
af
fin
ity
 (–
Lo
gIC
50
)
–10 –8
Log [ligand] (M)
–6 –4
%
 B
in
di
ng
 ve
rs
u
s
80
 p
M
 [1
25
l] -
 C
3a
 (1
00
%)
–28.4 –15.8 –18.0 0 kJ mol–1
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concentration) 7 nM versus 40 nM). Moreover, this agonist
activity for both C3a and 17 was dose-dependently inhibited to
the same degree by a known, albeit weakly potent antagonist of
C3aR (SB290157, IC50 (half maximal inhibitory concentration)
1 mM versus C3a at 1 mM)28,29, consistent with the effect being
mediated in both cases by C3aR (Fig. 4b). The high agonist
potencies of 17 and C3a are, in spite of their quite different
affinities for C3aR (Fig. 4c), the much greater affinity of C3a
being due to its additional large helical domain that binds to an
extracellular region of the receptor. The presence of this high-
affinity receptor-anchoring domain in C3a provides a high
effective molarity for the receptor-activating C-terminus of C3a,
which is otherwise a weakly binding and very feeble agonist
(compound 1, Table 1). Altering concentrations of both 17 and
SB290157 (ref. 29) revealed competition between the compounds,
evidenced by a horizontal shift to the right in agonist plots
(Fig. 4d), with a Schild plot slope B1 (Fig. 4e) consistent with
both compounds binding to the same or overlapping site on
C3aR. An important advantage of compound 17 over C3a is that
17 remains intact after exposure to plasma, whereas the arginine
is cleaved from C3a within minutes in plasma (Fig. 4f) by
carboxypeptidases26. The product of this cleavage is C3a-desArg,
which has quite a different pharmacology and a different
receptor44; thus, C3a is actually of little value as a tool to probe
C3aR-mediated functions induced in vivo by constitutive C3a.
The plasma stability of small molecule agonists such as 17 is likely
to be of enormous benefit for in vivo studies, provided that they
display other comparable functional responses to C3a, and can
therefore be used as small molecule surrogates for C3a (see
ahead).
Profiling additional agonist functions. Compound 17 was thus
also compared with recombinant human C3a for other functional
agonist responses using different assays and different cells.
Figure 5a–c shows that C3a and 17 induce comparable profiles of
expression of the inflammatory genes IL8, CCL3, FOSB, IL6 and
EGR1 in HMDMs. Moreover, IL1b and TNF gene expression
induced by either C3a or 17 was blocked by the known29, but
very weakly potent C3aR antagonist SB290157, by pertussis toxin
that decouples C3aR from Gi, and by the PLCb inhibitor U73122
that blocks C3aR-mediated Ca2þ release (Fig. 5b,c). These effects
are consistent with the actions of 17 being mediated through
C3aR and point to comparable potencies with C3a in the
responses being measured. Finally, in different human immune
cells, both C3a and 17 at nM to mM concentrations induced
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degranulation of human mast cells to the same extent, as
measured by comparable release of hexosaminidase (Fig. 5d).
Further, this agonist response was inhibited to the same extent for
C3a and 17 by SB290157 (Fig. 5e). These data give very strong
support for compound 17 being a viable, equipotent, functional
surrogate for the human C3a protein. We expect
that this compound class can be further developed into valuable
drug-like agonists and antagonists for treating C3aR-mediated
diseases.
Discussion
A method has been described for downsizing a protein to an
equipotent functional small molecule, a method that does not
require a crystal structure for the protein but does rely on some
knowledge of the activating region of the protein. The C3a
protein chosen here for mimicry has its functional activity
localized at its C-terminus, but requires the remainder of the
protein for high affinity binding to the receptor to elicit agonist
activity and high potency. In this study, the high affinity binding
domain of C3a has been removed, but compensated for by
making rational changes to small molecule mimics of the
C-terminal tripeptide segment of C3a, namely Leu–Ala–Arg.
These changes impart H-bond-accepting properties, introduce a
turn-inducing heterocycle and enhance space-filling properties of
the small molecule analogues. The results convincingly demon-
strate that a number of compounds (7, 8, 13, 16 and 17) have
equipotent agonist activity to the protein C3a, as measured by
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inflammatory genes in HMDMs, monitored by quantitative reverse-transcriptase PCR. Relative gene expression data are duplicates normalized to house-
keeping gene 18S. Fold changes were calculated against untreated control. Error bars represent mean±s.e.m. of at least three independent experiments.
*Po0.05; **Po0.01; ***Po0.005. (b,c) Expression in HMDMs of inflammatory genes IL1b and TNF induced by C3a or 17 (0.3mM, 30min) alone
or after preincubating cells with C3aR antagonist (10 mM SB290157, 30min), Gai inhibitor (200ngml 1 pertussis toxin (PTX), overnight) or PLCb inhibitor
(10mM U73122, 30min). (d,e) b-Hexosaminidase release mediated by C3a (pEC50 8.0±0.3) and 17 (pEC50 7.8±0.6) in the absence or presence of
SB290157 in LAD2 human mast cells. Cells were pre-sensitized with IgE (100 ngml 1, overnight) before adding C3a (1mM at 1.5 log dilutions) or 17 (10 mM
at 1.5 dilutions) for 30min. In the antagonist assay, cells sensitized overnight with IgE were incubated with SB290157 (100 mM at 1.5 log dilutions,
30min) before adding C3a or 17 (1mM) for 30min. Release of b-hexosaminidase in cell supernatant and lysate was detected by adding p-nitrophenyl
N-acetyl-b-D-glucosamide (PNAG) and reading absorbance at 405 nm. % b-Hexosaminidase release was calculated against response for 1 mM
agonist. Error bars represent mean±s.e.m. of (n¼4) independent experiments.
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induction of intracellular Ca2þ release in human macrophages
(Table 1). The most potent compound (17) was examined in
more detail in other cellular assays, with mimicry of potent C3a
function also extending to C3aR-mediated expression of all seven
selected inflammatory genes in human macrophages and to
C3aR-mediated degranulation of human mast cells. These
immunostimulating properties for 17 are the same as for human
C3a, validating successful functional mimicry of a protein by a
small molecule across a range of inflammatory and cellular
readouts.
Through structure–activity relationships, it has been shown
that six factors contribute to the spectacular agonist potencies of
these compounds, which are approximately six orders of
magnitude more potent than the Leu–Ala–Arg tripeptide
component of C3a but are not much different in size. (1) These
compounds possess an important arginine, just like the critical
C-terminal arginine of human C3a, which imparts some binding
affinity for C3aR. (2) All compounds possess an Ox or imidazole
heterocycle, which also provides (3) a strong H-bond-accepting
nitrogen atom, as well as (4) subtly altering the position of the
Leu/Ile side chain in the dipeptide surrogate (Leu/Ile–heterocycle)
versus Leu/Ile–Ala. These compounds further share (5) the
presence of an N-terminal carbonyl group that can make an
additional H-bond interaction with C3aR and (6) a Boc/Indole
capping group that can fill additional space in the receptor. The
relative contributions made by each of these components to
ligand affinity and agonist potency were ascertained via
structure–activity relationship studies (Table 1).
Collectively, these features have led to the rational develop-
ment of small molecules (molecular weighto500 Da) with high
affinity and specificity for the human C3a receptor and
comparable agonist potencies to C3a. The most potent
compound was profiled more extensively in multiple additional
assays where it was found to have the same C3aR-mediated
functional profile, selectivity, activities and potencies as human
C3a protein. Compound 17 was shown to be a potent and C3aR-
selective agonist surrogate for C3a (Supplementary Fig. S5), with
the advantage of being plasma stable unlike C3a, which rapidly
loses its C-terminal arginine along with its affinity for and
function through the receptor for C3a. Moreover, all the small
molecules described herein can be made at a fraction of the
thousands of dollars per milligram cost commercially charged
for human C3a.
This approach to potent small molecule protein mimics may
be transferable to the development of highly potent small
molecule mimics of other proteins, including other GPCR-
activating proteins. It is based on a very general premise, that
one may only need to know that an amino acid of a protein
(arginine here) is important for binding at a particular site on a
receptor protein, in this case through known effects on the
donor protein of site-directed mutagenesis of the receptor
protein. This single amino acid can then be grown through a
novel method of appending a H-bond-making entity, hetero-
cycles with graded H-bond acceptor versus H-bond donor
properties being chosen here to illustrate the idea. In principle,
this H-bond making appendage could be placed anywhere, on
one side or the other side, or both sides of the arginine (or other
point template) or further away. On finding measurable affinity,
the putative H-bond interaction can be rationally optimized by
increasing the H-bonding power, then by modifying the next
position adjacent to the heterocycle–arginine motif to rationally
improve binding and optimize function. Although only
exemplified here for one protein, this is a potentially general
approach. It remains to be determined whether its utility is also
general for developing small molecules with the functional
potencies of other proteins.
Methods
General methods. All reagents were purchased from Sigma-Aldrich or Chem-
Impex International Inc. Solid- and solution-phase chemistry approaches were
used to synthesize all final compounds. The purity of each compound investigated
was confirmed by 1H NMR spectroscopy, HPLC and high-resolution mass spectra
(HRMS). All compounds assayed were Z95% pure. The syntheses and char-
acterization of compounds 2–15 are reported in Supplementary Methods and
reaction schemes and spectroscopic data are provided in Supplementary Figs
S2–S20. The production and characterization of the two most potent compounds,
16 and 17, are described below. All final compounds were purified by reversed-
phase HPLC. Preparative-scale reversed-phase HPLC (rpHPLC) separations were
performed on a Phenomenex Luna C18 10 mm, 250 30.0mm column. Standard
conditions were used for elution of all compounds, unless otherwise indicated, at a
flow rate of 40mlmin 1: 100% A to 100% B linear gradient over 15min, followed
by a further 10min at 100% B where solvent B was 90% MeCN, 10% H2O±0.1%
TFA and solvent A was H2O±0.1% TFA. Compounds were detected by ultraviolet
absorption and pure fractions were lyophilized. Analytical rpHPLC was used to
assess compound purity (Phenomenex Luna C18 column, 5 mm, 90Å,
4.6 250mm, at three different wavelengths l¼ 214, 230 and 254 nm). Standard
conditions (same as preparative-scale rpHPLC) were used for all compounds,
unless otherwise indicated, at a flow rate of 1mlmin 1. Solvents were the same as
for preparative-scale rpHPLC. All final compounds were Z95% pure by analytical
HPLC. Electrospray ionization mass spectra measurements were obtained on
Micromass LCT. HRMS measurements were obtained on a Bruker microTOF mass
spectrometer equipped with a Dionex LC system (Chromeleon) in positive ion
mode by direct infusion in MeCN at 100 ml h 1 using sodium formate clusters as
an internal calibrant. Data were processed using Bruker Daltonics DataAnalysis 3.4
software. Mass accuracy was consistently better than 1 p.p.m. error. 1H and 13C
NMR spectra were recorded on Bruker Avance 600 or Varian 400 spectrometers at
298 K in the deuterated solvents indicated and were referenced to the residual 1H
signals; DMSO-d6 2.50 p.p.m. and CD3OD 3.31 p.p.m., except CDCl3 solutions
were referenced to internal tetramethylsilane (TMS). The exact concentration of
the compounds was determined by the quantitative NMR integration ‘PULCON’
experiment45. These settings were used for all PULCON experiments: relaxation
delay of 30 s, 64 scans, 2 dummy scans, 90 pulse and temperature at 298 K.
Synthesis of 3-indole-(Leu–Imidazole)–arg (16). Cbz–Leu–5-methylimidazole
ethyl ester (0.24 g, 0.6mmol) in MeOH (20ml) was treated with 10% Pd/C (20mg)
and hydrogenated at 40 psi on a Parr hydrogenator for 5 h. The mixture was filtered
through celite and the filtrate was concentrated in vacuo. The crude product was
added to N-Boc-indole-3-carboxylic acid (0.20 g, 0.70mmol), pre-activated (with
O-(Benzotriazol-1-yl)-N,N,N0 ,N0-tetramethyluronium hexafluorophosphate, diiso-
propylethylamine in dimethylformamide 2ml) and stirred overnight at room
temperature. The reaction mixture was diluted with ethyl acetate and washed with
saturated NaHCO3. The organic extracts were dried over MgSO4, filtered and
concentrated in vacuo. The crude product was dissolved in ethyl alcohol/H2O/2M
NaOH (4:1:1, 3ml) and heated in a microwave at 120 C for 10min. The ethyl
alcohol in the reaction was removed in vacuo and the aqueous solution was
acidified with 2M HCl and extracted with ethyl acetate. The combined organic
extracts were dried over MgSO4, filtered and concentrated in vacuo. The crude
product was coupled to H–Arg–OEt and then the ester was hydrolysed with
NaOH. The product was purified by rpHPLC and lyophilized to afford a white
powder (20mg, 7%). 1H NMR (600MHz, DMSO-d6), d 8.25 (br s, 1H), 8.17 (t,
J¼ 3.0Hz, 1H), 8.12 (d, J¼ 7.7Hz, 1H), 8.02 (br s, 1H), 7.59 (br s, 1H), 7.44 (d,
J¼ 7.7Hz, 1H), 7.15 (t, J¼ 7.8Hz, 1H), 7.10 (t, J¼ 7.6Hz, 1H), 5.36 (m, 1H), 4.41
(m, 1H), 3.17–3.08 (m, 2H), 2.43 (s, 3H), 1.96–1.82 (m, 2H), 1.80–1.63 (m, 3H),
1.56–1.49 (m, 2H), 0.96–0.92 (two sets of d, J¼ 6.6Hz, 6H). 13C NMR (150MHz,
DMSO-d6): d 173.3, 164.5, 158.7, 158.5, 158.3, 156.6, 136.3, 128.7, 126.3, 122.0,
120.9, 120.5, 111.9, 51.2, 44.5, 42.0, 40.3, 28.5, 25.3, 24.4, 22.8, 21.6, 10.5. HRMS
(m/z): [MH]þ calcd for C25H35N8O4þ , 511.2776; found, 511.2774; tR¼ 7.9min
(0–100% B in 10min gradient).
Synthesis of 3-indole–(Leu–Ox)–arg (17). This compound was synthesized fol-
lowing the same procedure for compound 16, except that H–Leu–Ox–OMe (0.11 g,
0.46mmol) was used for coupling to N-Boc-indole-3-carboxylic acid and gave 17
(27mg, 12%). 1H NMR (600MHz, DMSO-d6): d 8.59 (s, 1H), 8.39 (d, J¼ 8.6Hz,
1H), 8.22 (d, J¼ 8.6Hz, 1H), 8.16 (d, J¼ 3.0Hz, 1H), 8.11 (d, J¼ 7.9Hz, 1H),
7.55 (t, J¼ 5.8Hz, 1H), 7.43 (d, J¼ 8.2Hz, 1H), 7.15 (t, J¼ 7.4Hz, 1H), 7.09
(t, J¼ 7.6Hz, 1H), 5.36 (m, 1H), 4.40 (m, 1H), 3.14–3.06 (m, 2H), 1.96 (m, 1H),
1.87 (m, 1H), 1.83–1.75 (m, 2H), 1.69 (m, 1H), 1.56–1.45 (m, 2H), 1.00–0.91 (two
sets of d, J¼ 6.6Hz, 6H); 13C NMR (150MHz, DMSO-d6): d 173.5, 165.5, 164.8,
160.5, 157.1, 142.5, 136.5, 135.8, 128.8, 126.7, 122.4, 121.4, 120.9, 112.3, 110.0, 51.6,
45.2, 41.7, 40.8, 28.3, 25.8, 24.7, 23.3, 21.9. HRMS (m/z): [MH]þ calcd for
C24H32N7O5þ , 498.2459; found, 498.2461.; tR¼ 7.3min (20–100% B in 10min
gradient).
Calculations of H-bond interaction energy. The geometry of the water–
heterocycle H-bonded complex was optimized at the MP2/6-311þ þG(3d,3p)
level using Gaussian 09. The H-bond interaction energy was the difference
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in energy of the complex from the sum of energies of water and heterocycle,
calculated in isolation by the same method43.
Intracellular calcium release assay. HMDMs (5 104 cells per well) were added
to a 96-well cleared-bottom black-wall assay plate (Corning) and incubated over-
night at 37 C. Before assay, the medium was removed and cells were incubated
with dye-loading buffer (12ml Hank’s balance salt solution (HBSS) buffer, 4 mM
Fluo-3 AM, 25 ml Pluronic acid F-127 and 1% fetal bovine serum) for 1 h at 37 C.
Cells were then washed once with assay buffer (HBSS supplemented with 2.5mM
probenecid and 20mM HEPES, pH 7.4). Compounds were dissolved in dimethyl
sulphoxide (DMSO) to make a 10-mM stock solution, then further diluted with
HBSS buffer to the desired concentrations for intracellular calcium release assay.
Fluorescence imaging plate reader was used to monitor intracellular release of
Ca2þ via fluorescence measurement (excitation 495 nm, emission 520 nm) for
5min after injection of agonists. Changes in fluorescence (% response) were plotted
against logarithmic concentrations of test compound. The EC50 values were
derived from concentration response curves using nonlinear regression in
Graphpad Prism v5.
125I-C3a radioligand binding assay. Receptor binding was performed by ligand
competition with 80 pM [125I]-C3a (2,200 Cimmol 1; Perkin Elmer, Torrance,
CA, USA), HMDMs (1.2 106 cellsml 1), 80 pM [125I]-C3a±various con-
centrations of unlabelled C3a or test agonist mixed with solvent (50mM Tris,
3mMMgCl2, 0.1mM CaCl2, 0.5% (w/v) BSA, pH 7.4) for 60min in a 96-well Nunc
round-bottom plate at room temperature. Unbound [125I]-C3a was removed by
filtration through glass microfibre filter GF/B (Whatman Iner. Ltd, England),
which had been soaked in 0.6% polyethyleneimine to reduce nonspecific binding.
The filter was washed three times with cold buffer (50mM Tris-HCl), pH 7.4, and
bound [125I]-C3a was assessed by scintillation counting on Microbeta counter.
Specific [125I]-C3a binding was defined as the difference between total binding and
nonspecific binding as determined in the presence of 1 mM unlabelled C3a. The
IC50 value was derived from the concentration of agonist/antagonist required to
inhibit 50% of [125I]-C3a binding.
Gene analysis. HMDMs were seeded at 1 106 per ml and allowed to adhere
overnight. For inhibition experiments, HMDMs were pretreated with Gai inhibitor
(200 ngml 1 pertussis toxin, overnight) or PLCb inhibitor (10 mM U73122,
30min), or C3aR antagonist (10 mM SB290157, 30min), before adding C3a or 17
(0.3mM, 30min). RNA was extracted from HMDMs according to ISOLATE II
RNA Mini Kit (Bioline). Real-time PCR was measured on a ABI PRISM 7900HT
instrument (Applied Biosystems), each target gene was normalized to house-
keeping 18S rRNA and fold change was calculated relative to untreated control.
Primer sequence is shown in Supplementary Table S1.
Isolation of HMDMs. HMDMs were isolated using Ficoll-paque density centri-
fugation (GE Healthcare Bio-Science, Uppsala, Sweden) from buffy coat of
anonymous human donors provided by the Australian Red Cross Blood Service,
Brisbane. CD14þ monocytes were positively selected using CD14þ MACS
magnetic beads (Miltenyi Biotech, Auburn, CA, USA) after successive magnetic
sorting and washings. The CD14þ monocytes were then cultured at 37 C with 5%
CO2 and differentiated to HMDMs using 100 ngml 1 of recombinant human
macrophage colony-stimulating factor (PeptroTech Inc., Rocky Hill, NJ, USA)
at 1.5 106 cells per ml. HMDMs were kept in Iscove’s modified Dulbecco’s
media supplemented with 10% fetal bovine serum, penicillin (10Uml 1),
streptomycin (10Uml 1) and L-glutamine (2mM; Invitrogen). HMDMs were
supplemented after 5 days with fresh medium containing 100 ngml 1 macrophage
colony-stimulating factor. HMDMs were collected by gentle scraping in saline
solution on day 7.
b-Hexosaminidase release assay. LAD2 human mast cells (kindly provided by
Dr Dean Metcalfe, National Institute of Allergy and Infectious Diseases, National
Institute of Health) were cultured as previously described46 and b-hexosaminidase
release assay was performed as reported47. Briefly, LAD2 cells were presensitized
with IgE (100 ngml 1) overnight before experiment. In the antagonist assay,
SB290157 was pre-incubated for 30min before the addition of C3a or 17, and
release of b-hexosaminidase was measured at 405 nm using FLUOstar Optima
(BMG LabTechnologies).
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